Predictive Technology Group, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2018
February 15, 2019 at 08:00 am
Share
Predictive Technology Group, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended December 31, 2018. For the quarter, revenue was $10,687,036 against $3,378,526 a year ago. Operating loss was $2,075,632 against $482,859 a year ago. Net loss was $2,675,259 against $376,921 a year ago. Basic loss per share was $0.012 against $0.002 a year ago.
For six months, revenue was $18,750,838 against $5,413,934 a year ago. Operating loss was $4,138,584 against $5,717,461 a year ago. Net loss was $5,052,570 against $5,513,927 a year ago. Basic loss per share was $0.022 against $0.027 a year ago.
Predictive Technology Group, Inc. is a life science company. The Company, through its subsidiaries, is focused on specific points of the care continuum, including detection, prevention and treatment. Predictive Analytics, Predictive Laboratories, and Predictive Biotech each bring critical solutions to personalized patient care by leveraging its research, genomics, genetic library and expertise in developing bioscience solutions. Predictive Analytics is the repository for its genetic library. Predictive Biotech provides regenerative medicine. Its products are derived from tissue sources rich in properties that support the bodyâs natural ability to heal itself. All products are safely, ethically and minimally processed to deliver allografts that preserve the naturally occurring characteristics and factors of the donor tissue. Its research and use of processing methods has propelled its placental-derived and Whartonâs Jelly umbilical cord-derived products to new heights.